Search

everythinglearnresearchcommunity

for

Search:↓

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Leflunomide is more likely to help treat alopecia areata than cause it.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Alkylating agents can kill cancer cells but may cause skin and allergic reactions.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Early treatment with the right dose of stem cells can reduce lupus symptoms.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Tislelizumab can cause cutaneous lupus erythematosus.

Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

The scalp lotion helped increase hair thickness in cancer patients undergoing chemotherapy.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.